Sensei Biotherapeutics In... (SNSE)
Sensei Biotherapeutics Statistics
Share Statistics
Sensei Biotherapeutics has 25.21M shares outstanding. The number of shares has increased by 0.28% in one year.
| Shares Outstanding | 25.21M |
| Shares Change (YoY) | 0.28% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 9.34% |
| Shares Floating | 16.52M |
| Failed to Deliver (FTD) Shares | 1.12K |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 194.69K, so 0.77% of the outstanding shares have been sold short.
| Short Interest | 194.69K |
| Short % of Shares Out | 0.77% |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 0.29 |
Valuation Ratios
The PE ratio is -0.41 and the forward PE ratio is -0.49. Sensei Biotherapeutics's PEG ratio is 0.25.
| PE Ratio | -0.41 |
| Forward PE | -0.49 |
| PS Ratio | 0 |
| Forward PS | 0.8 |
| PB Ratio | 0.32 |
| P/FCF Ratio | -0.5 |
| PEG Ratio | 0.25 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sensei Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.7, with a Debt / Equity ratio of 0.1.
| Current Ratio | 7.7 |
| Quick Ratio | 7.7 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.15 |
| Interest Coverage | 362.38 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.15M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -66.67% in the last 52 weeks. The beta is 0.2, so Sensei Biotherapeutics's price volatility has been higher than the market average.
| Beta | 0.2 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 0.53 |
| Relative Strength Index (RSI) | 34.63 |
| Average Volume (20 Days) | 3.01M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -32.61M |
| Net Income | -30.16M |
| EBITDA | -32.61M |
| EBIT | -30.25M |
| Earnings Per Share (EPS) | -1.2 |
Balance Sheet
The company has 9.99M in cash and 3.85M in debt, giving a net cash position of 6.15M.
| Cash & Cash Equivalents | 9.99M |
| Total Debt | 3.85M |
| Net Cash | 6.15M |
| Retained Earnings | -262.05M |
| Total Assets | 53.25M |
| Working Capital | 42.66M |
Cash Flow
In the last 12 months, operating cash flow was -24.67M and capital expenditures -146K, giving a free cash flow of -24.82M.
| Operating Cash Flow | -24.67M |
| Capital Expenditures | -146K |
| Free Cash Flow | -24.82M |
| FCF Per Share | -0.99 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SNSE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SNSE is $4, which is 1112.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 1112.1% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -6.83 |
| Piotroski F-Score | 3 |